Alvimopan.
Alvimopan, a trans-3,4-dimethyl-4-(3-hydroxy-phenyl) piperidine, is a selective, peripherally acting micro-opioid receptor antagonist that is available for short-term use in hospitalized patients who have undergone bowel resection. The efficacy of alvimopan in the management of postoperative ileus has been evaluated in five phase III trials; four conducted in North America and one conducted in Europe/Australasia. Patients who had undergone partial large or small bowel resection surgery with primary anastomosis were randomized to receive alvimopan 12 mg or placebo as a single oral pre-operative dose followed by twice-daily administration for up to 7 days postoperatively. In the five phase III trials, alvimopan was significantly more effective than placebo in reducing the time to recovery of upper and lower gastrointestinal (GI) function, as assessed using a two-component endpoint (GI2) comprising time to tolerance of solid food and first bowel movement. The mean time to reach the GI2 endpoint was 11-26 hours sooner with alvimopan than with placebo. In the phase III trials conducted in North America, the time to writing the hospital discharge order was 13-21 hours sooner with alvimopan than with placebo. Alvimopan did not reduce opioid-induced analgesia and/or increase the amount of opioids administered postoperatively. Short-term alvimopan was generally well tolerated in adults undergoing bowel resection.
Curran
Monique P
MP
Wolters Kluwer Health | Adis, Auckland, New Zealand. demail@adis.co.nz
Robins
Gayle W
GW
Robyns
Gayle W
GW
Scott
Lesley J
LJ
Perry
Caroline M
CM
D000701:Analgesics, Opioid / Q000009:adverse effects; D000818:Animals; D013505:Digestive System Surgical Procedures; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D005767:Gastrointestinal Diseases / Q000139:chemically induced* / Q000188:drug therapy*; D005769:Gastrointestinal Motility / Q000187:drug effects; D006207:Half-Life; D006801:Humans; D010149:Postoperative Pain / Q000150:complications / Q000188:drug therapy; D010880:Piperidines / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D017450:Receptors, Opioid, mu / Q000037:antagonists & inhibitors*
D000701:Analgesics, Opioid; D005765:Gastrointestinal Agents; D010880:Piperidines; D017450:Receptors, Opioid, mu; C419502:alvimopan
Surg Endosc. 2006 Jan;20(1):64-70
16333556
Clin Pharmacol Ther. 2008 May;83(5):770-6
17653140
Surgery. 2007 Oct;142(4):478-86
17950339
Dis Colon Rectum. 2004 Apr;47(4):516-26
14978625
Aliment Pharmacol Ther. 2008 Aug 1;28(3):312-25
19086236
Ann Surg. 2004 Oct;240(4):728-34; discussion 734-5
15383800
J Med Chem. 1994 Jul 22;37(15):2262-5
8057274
Clin Gastroenterol Hepatol. 2003 Mar;1(2):71-80
15017498
Clin Pharmacol Ther. 2001 Jan;69(1):66-71
11180040
Clin Gastroenterol Hepatol. 2005 Aug;3(8):784-91
16234007
Am J Surg. 2001 Nov;182(5A Suppl):27S-38S
11755894
Dis Colon Rectum. 2005 Jun;48(6):1114-25; discussion 1125-6; author reply 1127-9
15906123
Arch Surg. 2003 Feb;138(2):206-14
12578422
J Am Coll Surg. 2007 Apr;204(4):609-16
17382220
Drugs. 2002;62(18):2603-15
12466000
Am J Surg. 2001 Nov;182(5A Suppl):3S-10S
11755891
Pharmacol Ther. 2008 Jan;117(1):162-87
18022696